Taipei medical university
Taipei, 116, Taiwan
NCT Number: NCT03867604
Patients with myofascial pain syndrome at upper trapezius will be randomized into 2 groups, fascial injection group and subcutaneous control injection group. Pain condition pain, range of motion and function will be evaluated in 1 week, 4 weeks and 12 weeks after injection.
Looking for future studies?
Notify Me20 year–70 year
All sexes
Interventional
Not applicable
Taipei, 116, Taiwan
Myofascial pain syndrome(MPS) is characterized by a trigger point with a hyperirritable nodule and taut band of muscle or fascia. MPS was usually treated by dry needling or met needing, local anesthetics injection, to the trigger point. According to recent researches, dry and wet needling to affected muscle are effectiveness for short term and medium term pain relief. Although some researches indicated an increased viscosity at fascial layer in MPS and there are few studies of manipulation for fascial release. There is not study of injective fascial release.
Investigators will include 40 patients with myofascial pain syndrome at upper trapezius. Participants will be randomized into 2 groups, fascia injection group and subcutaneous control injection group. Investigators will use algometer to measure pain threshold and peak pressure, measure the range of motion of neck and shoulder and assess the neck and shoulder function by questionnaire. The examination will be done before injection, immediately after injection, 1 week, 4 weeks and 12 weeks after injection.
To our hypothesis, investigators suggest focal anesthetics injection could decrease the fascial viscosity and improved pain and quality of life.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Injection to the subcutaneous layer at upper trapezium level
Injection to the fascia below upper trapezium muscle
Time frame: Change from baseline VAS at 1 week
visual analogue scale(VAS), range 0-10, the higher the worse pain
Time frame: Change from baseline VAS at 4 week
visual analogue scale(VAS), range 0-10, the higher the worse pain
Time frame: Change from baseline VAS at 12 week
visual analogue scale(VAS), range 0-10, the higher the worse pain
Time frame: Change from baseline SPADI at 1 week
Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse
Time frame: Change from baseline SPADI at 4 week
Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse
Time frame: Change from baseline SPADI at 12 week
Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse
Taipei Medical University WanFang Hospital
Other
Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle: A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05565053
Muscular Diseases, Musculoskeletal Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07503574
Muscular Diseases, Musculoskeletal Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07397039
Muscular Diseases, Musculoskeletal Diseases
Bangkok, Thailand
View Trial DetailsNCT06060925
Healthy, Muscular Diseases
Fairfax, Virginia, United States
View Trial Details